Replies to post #734478 on NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

Let's focus on something more fun for a moment. Have you read about the conclusion? It is certain that tumor-associated macrophage is the last hurdle before a final cure can be obtained. We can see the green dots from the combo trial. We can see the outstanding percentage of CD14 monocyte from the poly-iclc trial. We can see the TNFalpha measure from the Direct trial. In case you don't know, TNFalpha is derived from M2 tumor-associated macrophages.

Is CSF1R inhibitor the one that can deplete TAMs from tumor microenvironment? Remind me again which companies have the FDA approval CSF1R inhibitors.

I could be overzealous. I have full conviction that the longs will win big and whoever bets against this one will lose pathetically. Time will tell if I am right.

819 Temporal influence of PD-1 blockade after vaccination on macrophage-driven CD8+ T cell exhaustion within the glioblastoma microenvironment
https://jitc.bmj.com/content/12/Suppl_2/A927

Conclusions This study reveals that timing may impact how ATL-DC and aPD1 combined therapies can alter the immune landscape of GBM and highlights tumor-associated macrophages as a major obstacle to clinical benefit. Future strategies targeting these populations or blocking their immunosuppressive interactions with anti-tumor CD8+ T cells hold promise for improving the efficacy of immunotherapies in GBM.